Results 141 to 150 of about 36,274 (199)

Prognostic value of PSMA PET-derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. [PDF]

Cancer Imaging
Atasever T, Babacan GB, Ekinci ÖB, Buyukkuscu A, Uslu BS, Kabaca FZY, Atcı MM, Karyagar S, Ertürk K, Çelik E.   +9 more
europepmc   +1 more source

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy

BJU International, Volume 138, Issue 3, Page 430-437, September 2026.
Objectives To evaluate biochemical recurrence‐free survival (BRFS) and metastasis‐free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). Patients and Methods Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 ...
Navid Roessler, Zuzanna Nowicka, Marcin Miszczyk, Giorgio Calleris, Alessandro Dematteis, Malte W. Vetterlein, Simone Albisinni, Henk G Van Der Poel, Paul Cathcart, Giovanni E. Cacciamani, Inderbir S. Gill, Raj A. Persad, Steven Joniau, Rafael Sanchez‐Salas, Joseph A. Smith Jr, Robert Jeffrey Karnes, Mohamed E. Ahmed, Pawel Rajwa, Derya Tilki, Shahrokh F. Shariat, Paolo Gontero, Giancarlo Marra, on behalf of the Young Academic Urologists Prostate Cancer Working Party   +22 more
wiley   +1 more source

Limited Efficacy of Autologous Mesenchymal Stromal Cell Injections in Immunomodulatory‐Dependent Dogs With Aqueous Deficient Dry Eye Disease

Veterinary Ophthalmology, Volume 29, Issue 5, September 2026.
ABSTRACT Objective Aqueous deficient dry eye disease (ADDE) results from a quantitative reduction in aqueous tears. We sought to determine the clinical effect of autologous mesenchymal stromal cell (MSC) injections into the region of the lacrimal gland and the gland of the third eyelid in immunomodulatory‐dependent ADDE‐affected dogs. Methods Dogs (n = 
Brian C. Leonard, Shin Ae Park, Sun Young Kim, Kei Hayashi, Sara M. Thomasy, Vanessa Rozo, Monica J. Motta, Dori L. Borjesson, Christopher J. Murphy, Kathryn L. Good   +9 more
wiley   +1 more source

Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone. [PDF]

Cardiooncology
Bryce AH, Nimke D, Young C, Shao Q, Rozario N, Kamdar P, Ivanova J, Varghese I, Touya M.   +8 more
europepmc   +1 more source

Sustained Tear Film Exposure After Parenteral Cefovecin Administration in Dogs: Pharmacokinetics and Relevance to Canine Bacterial Keratitis

Veterinary Ophthalmology, Volume 29, Issue 5, September 2026.
ABSTRACT Objective To characterize the tear film pharmacokinetics of parenterally administered cefovecin (Convenia) and compare tear concentrations with the minimum inhibitory concentrations (MICs) of common ocular pathogens. Animals Studied Six healthy research‐bred Beagles.
Meredith R. McClure, Lionel Sebbag, David J. Borts, Rachel A. Allbaugh, Jessica L. Payne, Melissa A. Kubai   +5 more
wiley   +1 more source

Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer. [PDF]

Eur J Nucl Med Mol Imaging
Cockcroft M, Ferguson T, Meehan K, Al-Ogaili Z.   +3 more
europepmc   +1 more source

How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration data

Cancer, Volume 132, Issue 16, 15 August 2026.
In a retrospective analysis of Veterans Health Administration data for patients with metastatic castration‐sensitive prostate cancer (mCSPC), achieving a prostate‐specific antigen (PSA) of <0.2 ng/mL (whether or not a PSA decline of 90% was reached) within 9 months of initiating androgen deprivation therapy (ADT) ± other treatments was associated with ...
Stephen J. Freedland, Wei Gao, Maëlys Touya, Hongbo Yang, David Russell, Jingyi Chen, Grace Chen, Jasmina I. Ivanova   +7 more
wiley   +1 more source

Sequential nanocatalytic therapy and lysosomal dysfunction for overcoming castration-resistant prostate cancer. [PDF]

Bioact Mater
Di J, Lee W, Xu Y, Kong H, Zhou F, Xu J, Chen X, Lao YH, Shao D, Xie X, Yao H, Tao Y, Li M.   +12 more
europepmc   +1 more source

Radiation safety management for stereotactic body radiation therapy incidentally concurrent with Pluvicto® (Lu‐177) therapy ‐ a case report

Journal of Applied Clinical Medical Physics, Volume 27, Issue 8, August 2026.
Abstract A patient with castration‐resistant prostate cancer (CRPC) was referred to our clinic seeking palliative management of a painful metastasis in the left pelvis. At the time of referral, the patient was receiving [177Lu]Lu‐PSMA 617 (Pluvicto®) therapy at an outside institution, with the next scheduled administration approaching within days.
Dongxu Wang, Bae P. Chu, Maria F. Chan, Jeonghoon Park, Yolanda Scott, Puneeth Iyengar, Matthew Williams   +6 more
wiley   +1 more source

Nicotinamide N-methyltransferase as a therapeutic target in taxane-resistant castration-resistant prostate cancer. [PDF]

Cell Death Discov
Cevatemre B, Karyemez E, Bulut I, Syed H, Gönen M, Baykal AT, Bagci-Onder T, Acilan C.   +7 more
europepmc   +1 more source